Top Medical News
Will a bedtime snack help treat hyperglycaemia in type 2 diabetes?
Stephen Padilla, Yesterday
There is no convincing benefit to consuming a bedtime snack for glycaemic control in individuals with type 2 diabetes (T2D) or prediabetes, according to the results of a systematic review.
Maximum home BP predicts cardiovascular outcomes in T2D patients
In patients with type 2 diabetes (T2D), maximum home blood pressure (BP) may be used as a potential marker of subsequent cardiovascular events, suggests a retrospective cohort study.
Product Highlight - Cruzor
4 days ago
Irbesartan 300 mg FC tab
Product Highlight - Roxatin
4 days ago
Rosuvastatin 10 mg and 20 mg FC tab
Intermittent fasting may not be healthy after all
Elvira Manzano, 4 days ago
Currently in vogue, intermittent fasting (IF) – which switches between periods of eating and fasting – may not be as beneficial as many have thought.
CGM improves HbA1c levels in T1D
Roshini Claire Anthony, 5 days ago

Continuous glucose monitoring (CGM) with alarms for high or low blood sugar levels better controlled HbA1c levels than personal fingerstick monitoring in patients with type 1 diabetes (T1D), results of the FLASH-UK trial showed.

COVID-19 reinfection doubles the risk of death
Elvira Manzano, 26 Nov 2022
COVID-19 reinfection doubles the risk of death and triples the risk of hospitalization, with post-acute sequelae in the pulmonary and extra-pulmonary organ systems, in a new study.
Special Reports
Product Highlight - Cruzor
30 Nov 2022
Irbesartan 300 mg FC tab
Product Highlight - Roxatin
30 Nov 2022
Rosuvastatin 10 mg and 20 mg FC tab
Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 04 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Conference Reports
ESSENTIAL: Ezetimibe plus statin reduces liver fat
Elvira Manzano, 31 Oct 2022
Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.
Hysterectomy tied to increased diabetes risk
Roshini Claire Anthony, 21 Oct 2022

Undergoing a hysterectomy, particularly at a young age, may be associated with an increased risk of developing diabetes, according to a study from France presented at EASD 2022.

Beta-blocker shows potential for diabetic foot ulcers
Audrey Abella, 20 Oct 2022
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).
Sotagliflozin may offer cardiorenal protection for adults with T1D
Audrey Abella, 13 Oct 2022
Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).
Triple-drug combo reduces HbA1c in T2D
Elaine Soliven, 12 Oct 2022
Adding evogliptin, a novel dipeptidyl peptidase-4 inhibitor, to dapagliflozin and metformin significantly reduced HbA1c level in patients with uncontrolled type 2 diabetes (T2D), according to a study presented at EASD 2022.
Young age at diabetes diagnosis tied to worse outcomes
Roshini Claire Anthony, 09 Oct 2022

Individuals who are diagnosed with type 2 diabetes (T2D) at age 40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.

Tirzepatide confers renal protection in patients with T2D
Elaine Soliven, 05 Oct 2022
Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.